---
title: "Lysergide (DT120) in Generalized anxiety disorder: Executive summary: Disease burden"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Disease burden. 1 evidence topic quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary/disease-burden"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Generalized anxiety disorder

<a id="topic-1.1.1-1"></a>

### Summary

The Mental and Substance Use Disorders Prevalence Study, which interviewed close to 5,700 U.S. adults aged 18 to 65 between October 2020 and October 2022, reported a past-year prevalence of generalized anxiety disorder (GAD) of 10.0% (95% CI 8.3% to 12.1%), approximately 20.2 million adults; its report names the study's conduct during the COVID-19 pandemic as the most obvious explanation for rates higher than in past nationally representative studies. Other estimates of 12-month prevalence are 2.7% of U.S. adults aged 18 or older in the National Comorbidity Survey Replication, 3.1% in a second analysis of that survey, and 2.1% in a third study, which reported a lifetime prevalence of 4.1%. In U.S. claims of adults engaging with the healthcare system, projected annual prevalence of diagnosed GAD rose from 5.4% in 2020 to 6.6% in 2023, and annual incidence of newly diagnosed GAD ranged from 2.1% to 2.3%. A further study reported a 1-year incidence of DSM-IV GAD of 1.12 per 100 person-years at risk. Definium Therapeutics states that GAD affects approximately 26 million U.S. adults, citing the prevalence study, Census data, and internal company estimates.

Over 12 years of follow-up, patients with GAD had a recovery probability of 0.58 and a recurrence probability after recovery of 0.45. Worldwide, lifetime comorbidity was 81.9%, with major depressive disorder in 52.6% of lifetime cases. Compared with the general population, mortality rate ratios in GAD were 1.62 (95% CI 1.35 to 1.93) for all causes and 2.55 (2.00 to 3.19) for unnatural causes.

In the 2022 US National Health and Wellness Survey, adjusted EQ-5D index scores were 0.80, 0.75, and 0.66 in mild, moderate, and severe GAD against 0.84 in controls. Adjusted total direct costs were $11,711 in diagnosed and $18,045 in undiagnosed GAD against $9,190 without GAD, and indirect costs were $7,507, $7,805, and $6,532, respectively. Of U.S. adults with past-year GAD, 32.3% had serious impairment.

Source: [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report); [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf); [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder); [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/); [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/); [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/); [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/); [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf); [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/); [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/); [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/); [Duong et al. (2024a)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/137867); [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
